This early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will …
Phase: PHASE1, PHASE2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC